←
Endocrine Today24,721 posts
Endocrine Today avatar

Endocrine Today

@EndocrineToday

The content you need, when you need it.

◷ Joined March 2009▧ 1,661 Photos and videos
Endocrine Today avatar
Endocrine Today@EndocrineToday·5h

📉 At 68 weeks, children with #obesity receiving semaglutide had a 13.5% drop in BMI compared with a 2.7% BMI increase with placebo. More data from the STEP Young trial can be found ⬇️ @novonordiskus @YaleMed @ObesitySociety vist.ly/5tbzw

Endocrine Today avatar
Endocrine Today@EndocrineToday·5h

🧬 Researchers from @HenryFordHealth identified several molecular signatures that may help determine malignancy risk and the level of risk among #thyroid nodules. Read more about these two studies presented at #ATA2026 ⬇️ @AmThyroidAssn @ArtiBhan1 vist.ly/5tbyi

Endocrine Today avatar
Endocrine Today@EndocrineToday·23h

💡 At 72 weeks, teens with obesity experience a wide range of cardiometabolic improvements with tirzepatide, including 📌 lower triglycerides 📌 higher HDL cholesterol 📌 lower blood pressure @ObesityWeek @umnmedschool @EliLillyandCo @IDinChildren vist.ly/5t8yy

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 17

🆕In adults and children with acquired hypothalamic obesity, setmelanotide was linked to meaningful reduction in BMI at 2 years, researchers reported at #ObesityWeek. #OW26 @ObesityWeek @ObesitySociety @radychildrens @RhythmPharma vist.ly/5t7nv

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 17

📉 Adults with post-bariatric hypoglycemia receiving avexitide had reductions of 📌 63% in level 2 hypoglycemia 📌 47% in level 3 hypoglycemia Read more about this novel drug in our @ObesityWeek coverage 👇 @StanfordMed @AmylyxPharma @ObesitySociety vist.ly/5t7np

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 17

💉Cagrilintide/semaglutide 1.7 mg each and 1 mg each were linked to reduced body weight vs. placebo; the results suggest lower doses than the most-studied dose of 2.4 mg each can be effective. #ObesityWeek #OW26 @ObesityWeek @ObesitySociety @GoHealio vist.ly/5t6ng

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 16

🚨 Children with #obesity as young as age 6 years achieved a significant BMI reduction with #Wegovy, which could lead to a “paradigm shift” for treating the disease in youths. Learn more about the STEP Young trial presented at @ObesityWeek👇 vist.ly/5t3x8

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 16

🚨 Adolescents with #obesity experienced a 19% greater drop in BMI after receiving tirzepatide for 72 weeks compared with placebo. Read more about the SURMOUNT-ADOLESCENTS data presented @ObesityWeek 👇 @umnmedschool @EliLillyandCo @ObesitySociety vist.ly/5t36u

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 16

💡 Among adults using semaglutide or tirzepatide for #obesity treatment at baseline, weight loss was highest for 📌 those who underwent bariatric surgery and 📌 adults who switched between the two GLP-1 based therapies #ObesityWeek @HamletGasoyan vist.ly/5s26c

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 16

📱 According to @TandemDiabetes, people with #diabetes will be able to use Tandem Mobi either tubed or tubeless. The device is compatible with smartphones through a mobile app. The @US_FDA cleared a tubeless cartridge for Tandem Mobi on Nov. 13. vist.ly/5sz44

Endocrine Today avatar
Endocrine Today@EndocrineToday·Nov 15

🆕Semaglutide and tirzepatide were cost-effective at prices negotiated for the U.S. Military Health System, according to a presentation at #ObesityWeek. #OW26 @ObesityWeek @ObesitySociety @GoHealio @WRNMMC_DHA vist.ly/5swin